Advances in the therapy of Wegener's granulomatosis

Current Opinion in Rheumatology

Volumn 18, Issue 1, 2006, Pages 25-32

  Hellmich, Bernhard ^a   Lamprecht, Peter ^a   Gross, Wolfgang L ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cyclophosphamide; Methotrexate; Tumour necrosis factor; Wegener's granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; DRUG DERIVATIVE; GUANIDINE DERIVATIVE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; SPERGUALIN; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANCA ASSOCIATED VASCULITIS; ANEMIA; BLADDER CANCER; BONE MARROW DEPRESSION; CLINICAL TRIAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; LEUKOPENIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MYELODYSPLASIA; NEUROPATHY; PATIENT CARE; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; TREATMENT INDICATION; WEGENER GRANULOMATOSIS; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CYCLOPHOSPHAMIDE; GUANIDINES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; METHOTREXATE; MYCOPHENOLIC ACID; PLASMAPHERESIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; WEGENER GRANULOMATOSIS;

EID: 33645460045     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000200369.24793.f5     Document Type: Review

References (54)

1. Fauci A, Haynes B, Katz P, Wolff S. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76-85.
2. Hoffman G, Kerr G, Leavitt R, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-499.
3. Guillevin L, Cordier J, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40:2187-2198.
4. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43:1021-1032.
5. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
6. de Groot K, Jayne D, Tesar V, Savage C. Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis [abstract]. Kidney Blood Press Res 2005; 28:195.
7. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med 1997; 90:401-409.
8. de Groot K, Adu D, Savage C. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16:2018-2027.
9. de Groot K, Muhler M, Reinhold-Keller E, et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998; 25:492-495.
10. Sneller MC, Hoffman GS, Talar-Williams C, et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38:608-613.
11. de Groot K, Rasmussen N, Bacon P, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2462-2469. This is the first randomized controlled clinical trial demonstrating that methotrexate can replace cyclophosphamide in early systemic ANCA-associated vasculitis. The high relapse rates seen in that trial provide a rationale for a maintenance therapy beyond 2 months.
12. Reinhold-Keller E, De Groot K, Rudert H, et al. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. Q J Med 1996; 89:15-23.
13. Gaskin G, Pusey CD. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher 2001; 5:176-181.
14. Woolf SH. Practice guidelines: a new reality in medicine. III. Impact on patient care. Arch Intern Med 1993; 153:2646-2655.
15. de Groot K, Reinhold-Keller E, Tatsis E, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39:2052-2061.
16. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42:2666-2673.
17. Reinhold-Keller E, Fink C, Herlyn K, et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Care Res 2002; 47:326-332.
18. Metzler C, Wagner-Bastmeyer R, Gross W, Reinhold Keller E. Leflunomide versus methotrexate for maintenance of remission in Wegener's granulomatosis: unexpected high relapse rate under oral methotrexate. Ann Rheum Dis 2005; 64 (Suppl. 3):85. The first results of a randomized prospective multicentre trial comparing leflunomide and methotrexate given for the maintenance of remission in WG.
19. Metzler C, Fink C, Lamprecht P, et al. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology 2004; 63:339-340. The first study reporting the use of leflunomide for the maintenance of remission in 20 patients with WG in a prospective open-label design.
20. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335:16-20.
21. Nowack R, Gobel U, Klooker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10:1965-1971.
22. Haubitz M, de Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-assocaited vasculitis. Clin Nephrol 2002; 57:421-424.
23. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51:278-283. A small open-label trial in 14 patients with WG evaluating MMF for the maintenance of remission.
24. Schmitt WH, Birck R, Heinzel PA, et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005; 20:1083-1092.
25. Merkel PA, Cuthbertson D, Hellmich B, et al. Comparison of disease activity measures for ANCA-associated vasculitis. Arthritis Rheum 2004; 50 (Suppl):S229-S230.
26. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000; 93:433-439.
27. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44:1149-1154.
28. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41:1303-1307.
29. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717-721. This is so far the largest prospective trial evaluating the efficacy of infliximab given as an adjunct to standard therapy in patients with AAV.
30. Keogh K, Wylam M, Stone J, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262-268. The first prospective trial on rituximab given in addition to standard therapy in 11 patients with AAV. Although the therapeutic value of rituximab is difficult to assess in this study because of the use of various co-medications, the trial provides interesting insights on the effect of B-cell blockade on ANCA production.
31. Birck R, Warnatz K, Lorenz HM, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003; 14:440-447.
32. Aries PM, Hellmich B, Reinhold-Keller E, Gross WL. High-dose intravenous azathioprine pulse treatment in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2004; 43:1307-1308. The first report on the application of a high-dose azathioprine regimen in two patients with refractory WG.
33. Schmitt WH, Hagen EC, Neumann I, et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65:1440-1448. An open-label clinical trial on the use of antithymocyte globulin in refractory WG. Although some efficacy of antithymocyte globulin was reported, two of 15 patients in this study died from diffuse alveolar haemorrhage and infection.
34. Hollander D, Manning R. The use of alcylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967; 67:393-398.
35. Walton E. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ 1958; 2:265-270.
36. Knight A, Askling J, Granath F, et al. Urinary bladder cancer in Wegener's granulomatosis, risks and relation to cyclophosphamide. Ann Rheum Dis 2004; 63:1307-1311. An interesting epidemiological study in a large population indicating that patients with WG might have an increased risk of bladder cancer already before the exposure to cyclophosphamide.
37. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998; 41:1835-1844.
38. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114:463-469.
39. Mahr A, Pagnoux C, Cohen P, et al. Treatment of ANCA-associated vasculitides: corticosteroids and pulse cyclophosphamide followed by maintenance therapy with methotrexate or azathioprine: a prospective multicenter randomized trial (Wegent) [abstract]. Kidney Blood Press Res 2005; 28:194.
40. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111:1133-1145.
41. Benenson E, Fries JW, Heilig B, et al. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol 2005; 24:251-257.
42. Jayne D. Update on the European Vasculitis Study Group (EUVAS). Curr Opin Rheumatol 2001; 13:48-55.
43. TheWGET Research Group. Design of the Wegener's granulomatosis etanercept trial (WGET). Control Clin Trials 2002; 23:450-468.
44. The Wegener's Granulomatosis Etanercept (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361. This is the first large placebo-controlled clinical trial evaluating a tumour necrosis factor blocking agent in WG. As the trial was powered to study the efficacy of etanercept for maintenance therapy, the study design is insufficient to conclude on the efficacy of etanercept in refractory cases of WG.
45. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004(1):CD003574.
46. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004; 109:1718-1723. E-pub 22 March 2004. An interesting experimental study on the mechanism of action of infliximab in AAV indicating that infliximab may restore impaired vasodilator responses.
47. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774-1785.
48. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41:1126-1132.
49. Tatsis E, Reinhold-Keller E, Steindorf K, et al. Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum 1999; 42:751-756.
50. Hellmich B, Kausch I, Doehn C, et al. Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide? Ann Rheum Dis 2004; 63:1183-1185.
51. Sneller MC. Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum 2005; 52:1-5. An excellent editorial on the use of B-cell blockade in AAV.
52. Gaskin G, Jayne D. Adjuctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. J Am Soc Nephrol 2002; 13:F-FC010.
53. Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42:1149-1153.
54. Goek O, Stone J. Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol 2005; 17:257-264. A detailed comparative review on the CYCAZAREM, NORAM and WGET studies.